Britain says it will become the first country to offer all babies a vaccine for potentially fatal meningitis B after it reached a price deal with GlaxoSmithKline PLC.
Government health advisers recommended use of the Bexsero vaccine last year, and the government has spent months negotiating over the cost.
The drug was owned by Novartis, which recently sold most of its vaccines business to GlaxoSmithKline.
Health Secretary Jeremy Hunt said Sunday he was "very proud that we will be the first country in the world to have a nationwide Men B vaccination program."
Babies will receive the vaccine at two months, followed by two further doses.
Meningitis is a bacterial infection of the lining surrounding the brain and spinal cord that most commonly affects children and teenagers.
Explore further: FDA approves second vaccine against meningitis strain
© 2015 The Associated Press. All rights reserved.
Medical Xpress on facebook
Related Stories
FDA approves second vaccine against meningitis strain
Federal health regulators have approved a second vaccine to prevent a strain of bacteria that can cause deadly cases of meningitis.
Novartis meningitis vaccine used at 2nd US campus
(AP)—Swiss drug maker Novartis says a second U.S. university is using its new vaccine against meningitis B.
EU drug regulator OKs Novartis' meningitis B shot
Europe's top drug regulator has recommended approval for the first vaccine against meningitis B, made by Novartis AG.
FDA approves infant combo vaccine for meningitis
(AP) — The first vaccine that protects children as young as six weeks against two potentially deadly bacterial infections has won approval from U.S. health regulators.
New meningitis vaccine only cost-effective at low price
The ideal cost per dose for a new meningitis vaccine ranges from £3 up to a possible £22 only if several vaccine favourable factors all coincide, according to research which has analysed how to maximise ...
Recommended for you
US aims to cut antibiotic use
US President Barack Obama on Friday rolled out plans to cut inappropriate antibiotic use by half, in an effort to tackle drug resistance.
Ebola whole virus vaccine shown effective, safe in primates
An Ebola whole virus vaccine, constructed using a novel experimental platform, has been shown to effectively protect monkeys exposed to the often fatal virus.
FDA to scrutinize unproven alternative remedies (Update)
Federal officials plan to review the safety and evidence behind alternative remedies like Zicam and Cold-Eeze, products that are protected by federal law, but not accepted by mainstream medicine.
Questions over value of new antibiotics to tackle resistance
In the first installment of a new series, Peter Doshi, Assistant Professor at the University of Maryland School of Pharmacy and Associate Editor at The BMJ, asks why authorities are approving drugs with little evidence they d ...
The state of vaccine confidence: Early results of a Vaccine Confidence Index
A decade on from the Northern Nigeria polio vaccination boycott and its global costs to the polio eradication initiative, a new report examines global issues affecting vaccine confidence and hesitation since the new millennium.
Science, patients driving rare disease drug research surge
The global pharmaceutical industry is pouring billions of dollars into developing treatments for rare diseases, which once drew little interest from major drugmakers but now point the way toward a new era ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment